Inactive Instrument

Highlights Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial	Mar. 07	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Vivesto's International Patent Application for XR-18 Receives Positive Decision	Jan. 30	CI
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment	Dec. 28	CI
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil	Dec. 19	CI
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership	Nov. 23	CI
Vivesto AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Pharmaceutical Group Vivesto to Delist from Frankfurt Bourse	23-09-18	MT
Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study	23-08-04	CI
Vivesto AB Announces Positive Paccal Vet FDA Pre-Submission Meeting	23-06-16	CI
Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Vivesto AB Initiates Clinical Development of Paccal Vet in Veterinary Oncology	23-03-20	CI
Vivesto AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Vivesto Sublicensee To Cancel Swiss Regulatory Application For Cancer Drug	23-01-11	MT
Vivesto AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-17	CI
Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-25	CI
Lonza Enters Manufacturing Deal With Oasmia for Ovarian Cancer Drug	22-03-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

Highlights

Filters